Orphan drug status for ruxolitinib

Submitted by Ross Bonander Thu 11/17/2011

Share on Tumblr

Call (877) 399-6937 or click here to learn more about Cancer Treatment options.

The US Food & Drug Administration has conferred orphan drug status on ruxolitinib for the treatment of the bone marrow disease myelofibrosis.

Approval came on the heels of data from the COMFORT trial. This clinical trial enrolled 528 patients, all of whom were refractory or resistant to existing myelofibrosis therapy or were ineligible for an allogenic bone marrow transplantation. Furthermore, all patients had previously undergone a splenomegaly and were symptomatic.

Ruxolitinib is a twice daily oral inhibitor of the JAK1 and JAK2 enzymes , which become deregulated in myelofibrosis.

In people with myelofibrosis, scar tissue takes over their bone marrow. Blood cell production therefore falls to the liver and the spleen.

Source: HemOncToday

Call (877) 399-6937 or click here to learn more about Cancer Treatment options.

Support Groups

SupportGroups.com

For individuals, friends and families who are looking to connect during life's challenging times. Share personal experiences, evaluate information and get support during times of need, illness, treatment or recovery.

Cancer Support Groups

Find a Treatment Facility Near You

Click on a state below to find Lymphoma treatment options that could be right for you.

Select a State Below

The information provided on the Lymphoma Information Network is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational and educational purposes. The publication of this information does not constitute the practice of medicine, and this information does not replace the advice of your physician or other health care provider. Neither the owners or employees of LymphomaInfo.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.